Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2020

Dec 1, 2020

31971_dirs_2020-11-30_d8c5afff-569e-4ffe-bba2-b7d920e8c1e7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2020-11-25

Reporting Person: Hartman Curt R (Director, President, CEO and Chair)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-25 Common Stock M 136000 $39.87 Acquired 240051 Direct
2020-11-25 Common Stock F 92194 $106.14 Disposed 147857 Direct
2020-11-25 Common Stock S 2512 $105.4011 Disposed 145345 Direct
2020-11-27 Common Stock S 596 $105.0117 Disposed 144749 Direct
2020-11-30 Common Stock S 5192 $101.6893 Disposed 139557 Direct
2020-11-30 Common Stock S 1700 $102.7424 Disposed 137857 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-11-25 Options To Purchase Common Stock $39.87 M 136000 Disposed 2026-03-01 Common Stock (136000) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.84 to $105.83. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.34 to $102.25. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.355 to $103.36. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.

F4: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.